Ayurvedic Therapy in Migraine with Anutaila Nasya and Pathya A Remission for Twenty Weeks
Abstract
No abstract
References
1. www.ihs-classification.org/en/02_klassifikation
2. http://www.who.int/mediacentre/factsheets/fs277/en
3. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41(7):646-657.
4. VagbhataAshtangaHridaya with commentaries Sarvangasundara by Arundatta and Ayurvedarasayana by Hemadri; Ed.PtParadkarVaidya, publ by Krishnadas Academy, 1982 sutrasthanachapt 20th 20/ 37-39; 293.
5. Sushruta: Sushruta Samhita with Nibandha Sangraha commentary of Acharya Dalhana, Ed. Vaidya Jadvji Trikamji Acharya and Narayana Ram Acharya Kavyatirtha ; Published by Chaukhamba Sanskrit Sansthan,Varanasi; Edition 2009; Uttar Tantra. 25/15;166-167.
6. Agostoni E, Fumagalli L, Santoro P et al. Neurological Sciences. 2004;25( 3 )123-125
7. Villalón CM, Centurión D, Valdivia LF etal.Migraine: pathophysiology, pharmacology, treatment and future trends. CurrVascPharmacol. 2003;1(1):71-84.
8. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013 Dec; 154 Suppl 1:S44-53.
9. Hoffmann J, GoadsbyPJ. Emerging Targets in Migraine. CNS Drugs. 2014;28(1):11-7.
10. Tfelt-Hansen P, De Vries P, Saxena PR Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60(6):1259-87
11. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm.2014;20(1):22-33
12.Vaidya A. Reverse pharmacological correlates of ayurvedic drug actions. Indian J Pharmacol. 2006;38:311-5
13.Chakrapani, Chakradatta, commentary by Dr. Indradev Tripathishirorogachikitsa prakarana, ed . Acharya Ramanathdwivedi, 3 rd ed. Chowkhambha Sanskrit samsthan.Varanasi. 1997,373.
14.VagbhataAshtangaHridaya with commentaries Sarvangasundara by Arundatta and Ayurvedarasayana by Hemadri; Ed. By PtParadkarVaidya, publ by Krishnadas Academy, 1982 sutrasthanachapt 20th 20/1; 287.
15. Nisargi R, Mhytre R.A clinical study on the management of ardhavabhedhaka Vis –a vis Migrainal headache; UJHAM; 01(03):71-76
16. Pardrige WM. Blood brain barrier biology and methodology. J Neurovirol. 1999;5:5556-5569.
17. Shreevidya P,ShantharamKS,Hegde RC et al,Int J Res Ayurveda Pharm. 2013;4(6);825-830.
18. Daniela B, Laurian V, Isoflavonoids from Glycyrrhiza sp. and OnonisSpinosa; Farmacia. 2012;60, 5; 615-620.
19. Dhingra D1, Sharma A. Antidepressant-like activity of Glycyrrhizaglabra L. in mouse models of immobility tests. ProgNeuropsychopharmacolBiol Psychiatry. 2006; 30(3):449-54.
20. P. Muralidharan, G. Balamurugan and VenuBabu. Cerebroprotective effect of Glycyrrhizaglabra Linn. root extract on hypoxic rats. Bangladesh J Pharmacol. 2009;4: 60-64.
21. Zhan C, Yang J. Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion induced focal cerebral ischemia in rats. Pharmacol Res. 2006;53:303-09.
22. Dobbins Kr Saul RF Transient visual loss after licorice ingestion. J neuroophthalmology. 2000; 20:38-41.
23. Singh E, Sheel Sharma S,Dwivedi J, Sharma S. Diversified potentials of Ocimumsanctum Linn (Tulsi): An exhaustive survey J. Nat. Prod. Plant Resour. 2012;2(1):39-48
24. Ahmad A1, Khan MM, Raza SS, Javed H, Ocimum sanctum attenuates oxidative damage and neurological deficits following focal cerebral ischemia/reperfusion injury in rats. Neurol Sci. 2012; 33(6):1239-47.
25. Pandey R, Gupta S, Shukla V, Tandon S. Antiaging, antistress and ROS scavenging activity of crude extract of Ocimum sanctum (L.) in Caenorhabditiselegans (Maupas, 1900). Indian J Exp Biol. 2013;51(7):515-21.
26. Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. Indian J PhysiolPharmacol. 2005;49(2):125-31
27. Chow HH, Anavy N, Villalobos A. Direct Nose-Brain Transport of benzoylecgonine. Following intranasal administration in rats. J Pharm Sci. 2001; 90:1729-1735.
28. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives.Adv Drug Deliv Rev. 2005; 57:1640-1665.
2. http://www.who.int/mediacentre/factsheets/fs277/en
3. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41(7):646-657.
4. VagbhataAshtangaHridaya with commentaries Sarvangasundara by Arundatta and Ayurvedarasayana by Hemadri; Ed.PtParadkarVaidya, publ by Krishnadas Academy, 1982 sutrasthanachapt 20th 20/ 37-39; 293.
5. Sushruta: Sushruta Samhita with Nibandha Sangraha commentary of Acharya Dalhana, Ed. Vaidya Jadvji Trikamji Acharya and Narayana Ram Acharya Kavyatirtha ; Published by Chaukhamba Sanskrit Sansthan,Varanasi; Edition 2009; Uttar Tantra. 25/15;166-167.
6. Agostoni E, Fumagalli L, Santoro P et al. Neurological Sciences. 2004;25( 3 )123-125
7. Villalón CM, Centurión D, Valdivia LF etal.Migraine: pathophysiology, pharmacology, treatment and future trends. CurrVascPharmacol. 2003;1(1):71-84.
8. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013 Dec; 154 Suppl 1:S44-53.
9. Hoffmann J, GoadsbyPJ. Emerging Targets in Migraine. CNS Drugs. 2014;28(1):11-7.
10. Tfelt-Hansen P, De Vries P, Saxena PR Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60(6):1259-87
11. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm.2014;20(1):22-33
12.Vaidya A. Reverse pharmacological correlates of ayurvedic drug actions. Indian J Pharmacol. 2006;38:311-5
13.Chakrapani, Chakradatta, commentary by Dr. Indradev Tripathishirorogachikitsa prakarana, ed . Acharya Ramanathdwivedi, 3 rd ed. Chowkhambha Sanskrit samsthan.Varanasi. 1997,373.
14.VagbhataAshtangaHridaya with commentaries Sarvangasundara by Arundatta and Ayurvedarasayana by Hemadri; Ed. By PtParadkarVaidya, publ by Krishnadas Academy, 1982 sutrasthanachapt 20th 20/1; 287.
15. Nisargi R, Mhytre R.A clinical study on the management of ardhavabhedhaka Vis –a vis Migrainal headache; UJHAM; 01(03):71-76
16. Pardrige WM. Blood brain barrier biology and methodology. J Neurovirol. 1999;5:5556-5569.
17. Shreevidya P,ShantharamKS,Hegde RC et al,Int J Res Ayurveda Pharm. 2013;4(6);825-830.
18. Daniela B, Laurian V, Isoflavonoids from Glycyrrhiza sp. and OnonisSpinosa; Farmacia. 2012;60, 5; 615-620.
19. Dhingra D1, Sharma A. Antidepressant-like activity of Glycyrrhizaglabra L. in mouse models of immobility tests. ProgNeuropsychopharmacolBiol Psychiatry. 2006; 30(3):449-54.
20. P. Muralidharan, G. Balamurugan and VenuBabu. Cerebroprotective effect of Glycyrrhizaglabra Linn. root extract on hypoxic rats. Bangladesh J Pharmacol. 2009;4: 60-64.
21. Zhan C, Yang J. Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion induced focal cerebral ischemia in rats. Pharmacol Res. 2006;53:303-09.
22. Dobbins Kr Saul RF Transient visual loss after licorice ingestion. J neuroophthalmology. 2000; 20:38-41.
23. Singh E, Sheel Sharma S,Dwivedi J, Sharma S. Diversified potentials of Ocimumsanctum Linn (Tulsi): An exhaustive survey J. Nat. Prod. Plant Resour. 2012;2(1):39-48
24. Ahmad A1, Khan MM, Raza SS, Javed H, Ocimum sanctum attenuates oxidative damage and neurological deficits following focal cerebral ischemia/reperfusion injury in rats. Neurol Sci. 2012; 33(6):1239-47.
25. Pandey R, Gupta S, Shukla V, Tandon S. Antiaging, antistress and ROS scavenging activity of crude extract of Ocimum sanctum (L.) in Caenorhabditiselegans (Maupas, 1900). Indian J Exp Biol. 2013;51(7):515-21.
26. Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. Indian J PhysiolPharmacol. 2005;49(2):125-31
27. Chow HH, Anavy N, Villalobos A. Direct Nose-Brain Transport of benzoylecgonine. Following intranasal administration in rats. J Pharm Sci. 2001; 90:1729-1735.
28. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives.Adv Drug Deliv Rev. 2005; 57:1640-1665.
Published
2019-08-10
How to Cite
Ashok Vaidya, Dhuri K. (2019). Ayurvedic Therapy in Migraine with Anutaila Nasya and Pathya A Remission for Twenty Weeks. The Indian Practitioner, 68(8), 54-58. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/579
Section
Case Reports
